Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer-Reference-Cited by-同舟云学术

Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer

Published:2015-04-11 Issue:1 Volume:15 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Jedinak Andrej,Curatolo Adam,Zurakowski David,Dillon Simon,Bhasin Manoj K,Libermann Towia A,Roy Roopali,Sachdev Monisha,Loughlin Kevin R,Moses Marsha A

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/article/10.1186/s12885-015-1284-z/fulltext.html

Reference50 articles.

1. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19:1893–907.

2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.

3. Gooren L. Androgen deficiency in the aging male: benefits and risks of androgen supplementation. J Steroid Biochem Mol Biol. 2003;85:349–55.

4. Bosch JL, Hop WC, Kirkels WJ, Shröder FH. Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. Urology. 1995;46(3 Suppl A):34–40.

5. Guess HA. Epidemiology and natural history of benign prostatic hyperplasia. The Urol Clin North Am. 1995;22:247–61.

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolomics and Proteomics in Prostate Cancer Research: Overview, Analytical Techniques, Data Analysis, and Recent Clinical Applications;International Journal of Molecular Sciences;2024-05-07

2. Nutritional Proteomics: A Key to Unlocking Optimal Human Health;Archives of Pharmacy Practice;2024

3. Protein biomarker detection in prostate cancer: A comprehensive review of electrochemical biosensors;Sensors and Actuators Reports;2023-12

4. Development of a predictive model to distinguish prostate cancer from benign prostatic hyperplasia by integrating serum glycoproteomics and clinical variables;Clinical Proteomics;2023-11-21

5. DNA methylation biomarkers distinguishing early-stage prostate cancer from benign prostatic hyperplasia;Prostate International;2023-06